Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02867384

Recruitment Status : Recruiting

First Posted : August 15, 2016

Last Update Posted : June 24, 2022

See Contacts and Locations

Sponsor:

Collaborator:

Roche-Genentech

Information provided by (Responsible Party):

Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	October 2023
Estimated Study Completion Date :	October 2024

To Top